Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Growth arrest specific 2 like 2 (GAS2L2)
- Target
- GAS2L2
- Molecular classification
- Other (cytoskeletal linker protein, actin-binding protein), No evidence of receptor, enzyme, transporter, channel, or transcription factor activity
01
Overview
Growth arrest specific 2 like 2 (GAS2L2) is a cytoskeletal crosslinker protein that structurally and functionally bridges filamentous actin and microtubules via calponin homology and GAR domains[1][2][6]. This linkage is crucial for maintaining proper cytoskeletal organization, dynamics, and coordination, impacting cell shape, movement, ciliary function, and regulation of the cell cycle and apoptosis[2][4][6]. GAS2L2 is mainly expressed in skeletal muscle and airway cells, where it is essential for correct ciliary orientation. Genetic variants in GAS2L2 are associated with primary ciliary dyskinesia (PCD), a disorder affecting ciliary motility and orientation with potential implications for respiratory health[4]. GAS2L2 has been implicated as a radioresponsive gene in cancer, but is not an established therapeutic target nor is there evidence for interacting drugs[6].
- Other names
- GAS2-like protein 2GAR17GAS2-related protein on chromosome 17Growth arrest-specific protein 2-like 2CILD41
02
Mechanism of action
Not applicable (GAS2L2 is not an established drug target)
03
Biological functions
Cytoskeleton organizationRegulation of microtubule dynamics and stabilityCell cycle regulationCrosstalk between actin and microtubulesRegulation of ciliary orientation and performance in airway tissueInfluences cell shape and motilityMay be involved in cellular apoptosis and radioresponsive cell processes
04
Disease associations
Primary ciliary dyskinesia (specifically, subtype PCD-41)Possible involvement in cancer regulation and response to radiation therapyNo strong evidence for roles in inflammation, neurodegeneration, or cardiovascular disease
05
Safety considerations
None reported for clinical interventions, as GAS2L2 is not a drug targetMutations may contribute to disease such as primary ciliary dyskinesia, likely due to defects in ciliary orientation and function
06
Interacting drugs
None identified
07
Biomarkers
The presence or alteration of GAS2L2 may serve as a biomarker for primary ciliary dyskinesia (PCD), particularly in cases where cilia orientation is affected despite normal axoneme structure
Beyond the preview
Go deeper on Growth arrest specific 2 like 2 (GAS2L2).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Growth arrest specific 2 like 2 (GAS2L2).